Back to Evidence

Paper-scoped peptide mentionSequence reported

Bradykinin

PMC9705435::PEP000019

Source publication

Thiocarbazate building blocks enable the construction of azapeptides for rapid development of therapeutic candidates.

Nature Communications · 2022

DOI 10.1038/s41467-022-34712-9 PMC9705435 PMID 36443291

Sequence status: reported
Standardization: Sequence ready
Source location: unknown
Activity records: 4

Sequence evidence

Reported molecular identity

RPPGFSPFR

Table 4 entry 1: RPPGFSPFR (Bradykinin)

Resolved peptide links

PEPDIA-PLP-003998 CTPDB_P058212

Experimental observations

Records linked to this mention

Metabolic/CardiovascularOtherPositive observation

Table 4 entry 1: Bradykinin ex-vivo stability t1/2 5.29 ± 0.5 min

Mention PMC9705435::PEP000019PMC9705435unknown

Measure: other
Value: 5.29 ± 0.5 min (half_life)
Target: Mus musculus
Assay: Not reported by source

Source publication

Metabolic/CardiovascularOtherPositive observation

Figure 4b: Bradykinin injection induced a decrease in MAP (~Δ 23 mmHg)

Mention PMC9705435::PEP000019PMC9705435unknown

Measure: other
Value: ~Δ 23 mmHg
Target: Rattus norvegicus
Assay: Not reported by source

Source publication

Metabolic/CardiovascularOtherPositive observation

Figure 5a: Bradykinin B2R binding IC50 low nM range

Mention PMC9705435::PEP000019PMC9705435unknown

Measure: other
Value: low nM range
Target: B2R
Assay: Not reported by source

Source publication

ImmunomodulatoryOtherPositive observation

Figure 5a: Bradykinin EC50 for PGE2 release in nanomolar range

Mention PMC9705435::PEP000019PMC9705435unknown

Measure: EC50
Value: nanomolar range
Target: 3T3
Assay: Not reported by source

Source publication

Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.